Zacks Research Analysts Lower Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research lowered their Q1 2025 EPS estimates for shares of Ironwood Pharmaceuticals in a note issued to investors on Wednesday, February 12th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.03. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q2 2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.11 EPS and Q4 2026 earnings at $0.10 EPS.

A number of other equities research analysts have also recently commented on the stock. JMP Securities cut their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $1.92 on Friday. The firm has a market cap of $307.26 million, a P/E ratio of -64.00 and a beta of 0.29. Ironwood Pharmaceuticals has a fifty-two week low of $1.59 and a fifty-two week high of $15.65. The firm has a 50-day simple moving average of $3.54 and a two-hundred day simple moving average of $4.10.

Insider Activity

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 208,742 shares of company stock valued at $405,343 in the last ninety days. 12.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of IRWD. Pacer Advisors Inc. raised its stake in shares of Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after buying an additional 450,949 shares during the period. State Street Corp raised its stake in Ironwood Pharmaceuticals by 7.3% during the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after acquiring an additional 677,024 shares during the period. Renaissance Technologies LLC lifted its holdings in Ironwood Pharmaceuticals by 5.5% during the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock valued at $40,163,000 after purchasing an additional 469,043 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock worth $14,652,000 after purchasing an additional 13,028 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock worth $8,786,000 after purchasing an additional 78,969 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.